Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2021-01-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于控股股东部分国有股权无偿划转的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1073 characters) regarding a change in the shareholding structure of the company's controlling shareholder due to a transfer of state-owned shares to a social security fund. It explicitly states that the control of the company remains unchanged. There is no financial data, no detailed report, no meeting materials, no voting results, no legal proceedings, no executive changes, and no mention of earnings or capital raising. The document is a regulatory announcement about a shareholding change but not a major shareholding notification crossing thresholds, nor a full report. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories and is not a full report or detailed filing.
2021-01-18 Chinese
哈药集团股份有限公司2021年第二次临时股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the 2021 second extraordinary shareholders' meeting of Harbin Pharmaceutical Group Co., Ltd. It includes meeting agenda, voting procedures, and detailed proposals related to labor relations adjustments and dismissal benefits under a reform plan. The content is focused on the meeting materials for a shareholders' meeting rather than a report of financial results or an announcement of voting results. The document length is 3550 characters, which is relatively short but contains detailed meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2021-01-15 Chinese
哈药集团股份有限公司关于选举职工监事的公告
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the election of an employee supervisor (职工监事) to the company's supervisory board. It includes a statement from the board and a brief resume of the elected individual. There is no financial data, no mention of annual or quarterly reports, no voting results from a general meeting, and no indication of a report publication. The content is about board/management information, specifically about the election of a supervisory board member. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is very short (407 characters), consistent with an announcement rather than a full report.
2021-01-08 Chinese
哈药集团股份有限公司关于“三项制度”改革实施劳动关系调整暨计提辞退福利的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 哈药集团股份有限公司 regarding the implementation of labor relations adjustments and the provision for dismissal benefits as part of a "Three Systems" reform. It details the number of employees affected, the estimated costs, and the accounting treatment of these dismissal benefits. The document includes opinions from independent directors and the supervisory board, and it states that the matter will be submitted to the shareholders' meeting for approval. The content is focused on a specific corporate governance and labor restructuring event, with financial implications but no comprehensive financial statements or full report. The document length is 2902 characters, which is relatively short and reads as an announcement rather than a full report. It does not contain full financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is not a certification or officer attestation, so it is not Regulatory Filings (RNS). It is not a remuneration report, call transcript, or other categories. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about labor reform and related accounting provisions, which does not fit other specific categories.
2021-01-08 Chinese
哈药集团股份有限公司独立董事关于计提辞退福利的独立意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors providing their independent opinion on the company's decision to accrue dismissal benefits related to labor relations adjustments. It references compliance with company law and accounting standards, and confirms the decision's legitimacy and alignment with shareholder interests. The document is short (323 characters) and does not contain financial statements or detailed financial data. It is an opinion letter related to a specific corporate governance matter rather than a full audit report or annual report. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, especially since it discusses accounting treatment and compliance. FY 2020
2021-01-08 Chinese
哈药集团股份有限公司关于召开2021年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2021 second extraordinary general meeting of shareholders (临时股东大会) for 哈药集团股份有限公司. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings, or report content. It is an announcement related to a shareholder meeting, specifically a notice to shareholders about the meeting and voting procedures. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 2819 characters, which is consistent with a meeting notice rather than a full report or results announcement.
2021-01-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.